{"id":"idp-126-gel","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Scaling"},{"rate":null,"effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IDP-126 Gel is a novel retinoid compound formulated for topical application. It works by binding to retinoid receptors in the skin, which helps normalize keratinocyte differentiation, reduce inflammatory cytokine production, and improve skin barrier function. This mechanism makes it suitable for treating inflammatory skin disorders.","oneSentence":"IDP-126 is a topical retinoid that modulates retinoid receptor signaling to reduce inflammation and promote skin cell differentiation in dermatological conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:32.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT07205107","phase":"","title":"Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2025-10-02","conditions":"Acne Vulgaris","enrollment":200},{"nctId":"NCT04892706","phase":"PHASE2","title":"Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2021-06-11","conditions":"Acne Vulgaris","enrollment":686},{"nctId":"NCT04214652","phase":"PHASE3","title":"Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2020-01-27","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT04214639","phase":"PHASE3","title":"Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2020-01-17","conditions":"Acne Vulgaris","enrollment":183},{"nctId":"NCT03170388","phase":"PHASE2","title":"A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2017-10-05","conditions":"Acne Vulgaris","enrollment":741},{"nctId":"NCT03653403","phase":"PHASE1","title":"Open-Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics of Topically Applied IDP-126 Gel in Comparison With Control Gel","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2018-08-08","conditions":"Acne Vulgaris","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IDP-126"],"phase":"phase_3","status":"active","brandName":"IDP-126 Gel","genericName":"IDP-126 Gel","companyName":"Bausch Health Americas, Inc.","companyId":"bausch-health-americas-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IDP-126 Gel is a small molecule being studied as a potential treatment for Acne Vulgaris. It is being compared to control gel, clindamycin phosphate, adapalene, and benzoyl peroxide in clinical trials.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":5,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}